Sec Form 13D Filing - Woodbridge Co Ltd filing for - 2026-04-17

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to rows 8 and 10 above, includes 300,790,959 common shares of Thomson Reuters Corporation ("Common Shares") beneficially owned by The Woodbridge Company Limited and subsidiaries and 11,727,129 Common Shares beneficially owned by the family of the late Roy H. Thomson, the first Lord Thomson of Fleet through various affiliated corporations. In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D



Comment for Type of Reporting Person:
In reference to row 13 above, based on 442,934,310 Common Shares outstanding as of March 31, 2026.


SCHEDULE 13D

 
THOMSON INVESTMENTS LIMITED
 
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
THE WOODBRIDGE COMPANY LIMITED
 
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
1908720 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
1000706525 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
1396164 Ontario Limited
 
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
1925124 Ontario Limited
 
Signature: /s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
Woodbridge Investments Corporation
 
Signature:/s/ Michael Medline
Name/Title:CEO & President
Date:04/17/2026
 
KRT INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
DKRT FAMILY CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
DKRT INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
DKRT FUNDING CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1000920847 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
MB FINANCE CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
TT INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
TLT INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
TLT ISSUE HOLDCO A CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
TLT ISSUE HOLDCO CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1761173 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
2677295 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1000919995 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1754693 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
PJT INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1000920848 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
PGF INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
PGF FAMILY CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
LCC INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1000078931 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1000421133 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
LLD INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
2806335 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
JRD INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
2754783 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
GED INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
SEG INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1000031857 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
SEG FAMILY CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
TCM INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
DYM INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title: Attorney-in-fact
Date:04/17/2026
 
BG INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
ACG INVESTMENTS CORP.
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
1001404651 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
 
2808194 ONTARIO LIMITED
 
Signature:/s/ Michael Medline
Name/Title:Attorney-in-fact
Date:04/17/2026
primary_doc.xml